Benefits
Benign Prostatic Hyperplasia (BPH) Symptom Improvement
Cochrane review (Wilt 2002) of 18 RCTs (n=1,562) showed pygeum significantly improved urinary symptoms (urgency, frequency, nocturia, urinary flow) vs placebo. One of the better-evidenced herbal BPH treatments. Effect smaller than alpha-blockers (tamsulosin) or 5-alpha-reductase inhibitors (finasteride) but reasonable adjunct.
Reduces Nocturia (Nighttime Urination)
Particularly effective at reducing nocturia frequency — a major quality-of-life symptom in BPH. Improvements consistent across multiple trials.
Improves Urinary Flow Rates
Modest but consistent improvements in peak urinary flow rate (Qmax) on uroflowmetry. Reflects reduced bladder outlet resistance.
Anti-Inflammatory Effects on Prostate
Pygeum has documented anti-inflammatory effects on prostatic tissue — reduces inflammation in chronic prostatitis and BPH. Particularly relevant given inflammation contribution to BPH pathology.
Sexual Function Preservation
Unlike finasteride (which can cause sexual side effects in some men), pygeum has neutral or possibly mildly positive sexual function effects. Important quality-of-life consideration.
Mechanism of action
5-Alpha-Reductase Inhibition (Modest)
Pygeum compounds modestly inhibit 5-alpha-reductase — reducing conversion of testosterone to dihydrotestosterone (DHT). Same target as finasteride but much weaker. Contributes to anti-BPH effects.
Anti-Inflammatory Activity
Pygeum reduces leukotriene synthesis and 5-lipoxygenase activity in prostatic tissue — reducing inflammation that contributes to BPH symptoms and pathology.
Bladder Function / Detrusor Muscle Effects
Improves bladder smooth muscle (detrusor) contractility — reducing urinary retention and improving voiding. Less smooth muscle relaxation than alpha-blockers (tamsulosin).
Phytosterol Effects
Beta-sitosterol and other phytosterols have direct anti-inflammatory and prostate-modulating effects. Additive to other prostate-focused supplements (saw palmetto, beta-sitosterol).
Clinical trials
Cochrane systematic review of 18 RCTs (n=1,562) of pygeum vs placebo or active controls for BPH symptoms.
1,562 BPH patients pooled.
Pygeum significantly improved overall symptom scores, nocturia, urinary flow vs placebo. Effect size modest. Generally well-tolerated. Established pygeum as evidence-based BPH herbal option.
Trials comparing pygeum directly with alpha-blocker tamsulosin for BPH.
BPH patients.
Tamsulosin generally superior to pygeum for symptom control; pygeum better tolerated with fewer sexual side effects. Combination may provide complementary benefits in some patients.
About this ingredient
Pygeum is the EXTRACT from the BARK of the AFRICAN CHERRY TREE (Prunus africana, formerly classified as Pygeum africanum). Native to high-elevation forests of CENTRAL AND EASTERN AFRICA — particularly Cameroon, Madagascar, Kenya, Uganda.
CRITICAL CONSERVATION CONCERN: pygeum overharvesting has caused severe population decline; CITES Appendix II protected (regulated international trade); CHOOSE SUSTAINABLY-SOURCED CULTIVATED PRODUCTS to avoid contributing to wild population depletion.
KEY ACTIVE COMPOUNDS: (1) PHYTOSTEROLS — primarily beta-sitosterol; (2) PENTACYCLIC TRITERPENES — ursolic acid, oleanolic acid; (3) FERULIC ACID ESTERS — n-tetracosanol, n-docosanol; (4) Tannins. STANDARDIZED EXTRACTS: typically standardized to 14% triterpenes and 0.5% beta-sitosterol. PRESCRIPTION DRUG STATUS in France (Tadenan®), Italy, Germany — recognized BPH treatment in European medicine.
CRITICAL EVIDENCE-BASED CONTEXT: pygeum has STRONGER EVIDENCE BASE than most herbal supplements — Cochrane review of 18 RCTs is among the most comprehensive evidence reviews for any supplement.
EVIDENCE-BASED USES: (1) BPH SYMPTOMS — established (Wilt 2002 Cochrane); (2) Chronic prostatitis adjunct; (3) Nocturia reduction; (4) Urinary flow improvement; (5) Combined with saw palmetto for prostate; (6) Sexual function preservation in men with BPH (unlike finasteride).
CRITICAL CAUTIONS: (1) BPH IS NOT PROSTATE CANCER — pygeum addresses BPH symptoms but is NOT cancer treatment; men with BPH should still get appropriate prostate cancer screening (PSA, DRE); (2) PSA EFFECTS — pygeum may modestly affect PSA — different from finasteride (which halves PSA); discuss with urologist for PSA interpretation; (3) MEDICAL EVALUATION FIRST — new urinary symptoms in men >50 warrant medical evaluation to rule out: prostate cancer, urinary tract infection, bladder cancer (less common), neurogenic causes; supplements should not delay diagnosis; (4) SEVERE BPH — pygeum is reasonable for mild-moderate BPH; severe BPH with significant symptoms or complications (urinary retention, recurrent UTIs, bladder stones, kidney damage) warrants prescription medications (alpha-blockers, 5-ARIs) and possibly surgical evaluation; (5) ACUTE URINARY RETENTION — emergency situation; not a 'try supplements first' situation; (6) PREGNANCY/LACTATION — not relevant (men's product) but theoretical caution if women using for other purposes; AVOID; (7) CONSERVATION — choose sustainably-sourced cultivated pygeum; wild harvesting contributes to species decline; (8) DOSE — 100-200 mg/day standardized extract; Tadenan® prescribing standard 50 mg BID; (9) DURATION — typically used long-term (6+ months) for chronic BPH symptom management; safe profile supports this; (10) COMBINATION with saw palmetto, beta-sitosterol, nettle root common in 'prostate formulas'; additive effects; (11) FOR ED concerns separate from BPH, pygeum is NOT primary treatment; consult appropriately; (12) PYGEUM vs SAW PALMETTO — both have evidence; saw palmetto more popular and cheaper; pygeum has Cochrane-level evidence; reasonable to use either or combine.